Mirum Pharmaceuticals, Inc. $MIRM Shares Sold by Boone Capital Management LLC

Boone Capital Management LLC reduced its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 16.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 535,732 shares of the company’s stock after selling 105,716 shares during the quarter. Mirum Pharmaceuticals makes up 12.9% of Boone Capital Management LLC’s portfolio, making the stock its 2nd largest holding. Boone Capital Management LLC’s holdings in Mirum Pharmaceuticals were worth $39,275,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. MCF Advisors LLC increased its holdings in Mirum Pharmaceuticals by 76.4% in the 3rd quarter. MCF Advisors LLC now owns 427 shares of the company’s stock valued at $31,000 after buying an additional 185 shares during the period. Quantbot Technologies LP bought a new position in shares of Mirum Pharmaceuticals during the 3rd quarter worth about $33,000. CWM LLC boosted its position in shares of Mirum Pharmaceuticals by 30.8% during the 3rd quarter. CWM LLC now owns 683 shares of the company’s stock valued at $50,000 after acquiring an additional 161 shares in the last quarter. Comerica Bank boosted its position in shares of Mirum Pharmaceuticals by 45.1% during the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after acquiring an additional 278 shares in the last quarter. Finally, Jones Financial Companies Lllp increased its stake in Mirum Pharmaceuticals by 34.0% in the third quarter. Jones Financial Companies Lllp now owns 957 shares of the company’s stock valued at $70,000 after acquiring an additional 243 shares during the period.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $130.00 price target on shares of Mirum Pharmaceuticals in a research report on Monday, December 8th. TD Cowen upped their price objective on Mirum Pharmaceuticals from $115.00 to $117.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a report on Thursday, January 22nd. HC Wainwright raised their target price on Mirum Pharmaceuticals from $102.00 to $130.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Finally, Raymond James Financial reiterated a “strong-buy” rating and issued a $110.00 price target on shares of Mirum Pharmaceuticals in a research report on Thursday, December 11th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $117.00.

Insider Buying and Selling at Mirum Pharmaceuticals

In related news, COO Peter Radovich sold 2,631 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $103.30, for a total value of $271,782.30. Following the completion of the transaction, the chief operating officer owned 20,655 shares in the company, valued at $2,133,661.50. The trade was a 11.30% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Patrick J. Heron acquired 131,425 shares of Mirum Pharmaceuticals stock in a transaction on Friday, January 23rd. The shares were purchased at an average cost of $68.48 per share, for a total transaction of $8,999,984.00. Following the acquisition, the director owned 459,010 shares in the company, valued at approximately $31,433,004.80. This represents a 40.12% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders sold 45,136 shares of company stock valued at $4,352,029 over the last three months. Insiders own 14.36% of the company’s stock.

Mirum Pharmaceuticals Stock Performance

Mirum Pharmaceuticals stock opened at $90.66 on Friday. The stock has a 50-day simple moving average of $95.39 and a 200 day simple moving average of $80.68. The stock has a market capitalization of $5.47 billion, a price-to-earnings ratio of -188.87 and a beta of 0.52. The company has a quick ratio of 2.55, a current ratio of 2.67 and a debt-to-equity ratio of 0.98. Mirum Pharmaceuticals, Inc. has a 12-month low of $36.88 and a 12-month high of $109.28.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Wednesday, February 25th. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.13). The company had revenue of $148.93 million for the quarter, compared to the consensus estimate of $141.78 million. Mirum Pharmaceuticals had a negative return on equity of 8.53% and a negative net margin of 4.48%.The firm’s revenue was up 49.8% compared to the same quarter last year. During the same period in the prior year, the company earned $1.00 EPS. On average, research analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.